News Sentiment

AIDX sentiment intelligence

20/20 Biolabs, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 0.59 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-4.2% over one week, -38.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.2% Price reacting lower
Trend fit Trend inactive -38.8% over four weeks
Fair value -72.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 33
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 5
TradingView 4
StockStory 3
Barron's 2
Investing.com 2
Kavout | AI 1
DirectorsTalk Interviews 1

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 20
Regulatory and legal 2
Balance sheet 1
Analyst action 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
TradingView Direct company coverage

Price to earnings forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX

This page displays the "Price to earnings forward" value for 20/20 Biolabs, Inc. (NASDAQ: AIDX). The content indicates that the value is currently absent or not provided. The page is sourced from TradingView and provides financial data for the company.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 09:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX

The article focuses on the "Price to book forward" metric for 20/20 Biolabs, Inc. (NASDAQ: AIDX). It appears to be a stub or a data point from a financial platform like TradingView, indicating a specific financial ratio for the company. The content primarily shows the title of th

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 18:11
Source
TradingView
TradingView Direct company coverage

20/20 Biolabs, Inc. Actuals & Estimates (NASDAQ:AIDX)

This article provides an overview of 20/20 Biolabs, Inc. (NASDAQ: AIDX) stock performance, financial estimates, and key company data. It includes details such as current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, alon

Tone
Negative 38/100
Event
Earnings
Published
25 Jun 2026 17:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX

This article focuses on the "Price to sales forward" financial metric for 20/20 Biolabs, Inc. (NASDAQ: AIDX). It appears to be a page from TradingView, displaying company financials and market data.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:09
Source
TradingView
Stock Titan Direct company coverage

20/20 BioLabs starts monthly webinars, with a OneTest discount for attendees

20/20 BioLabs (Nasdaq: AIDX) has launched a monthly investor webinar series, with the inaugural session on July 1, 2026, at 12:00 p.m. ET. These 45-minute webinars will occur on the first Wednesday of each month to provide updates, direct access to management, and a promotional d

Tone
Positive 61/100
Event
Market update
Published
24 Jun 2026 20:41
Source
Stock Titan
Stock Titan Direct company coverage

Large share authorization and new equity plan up for 20/20 Biolabs (AIDX) vote

20/20 Biolabs, Inc. (AIDX) is proposing several key changes for stockholder approval at its August 18, 2026, virtual annual meeting, including electing six directors, ratifying its auditor, approving a major charter change to increase authorized common stock from 50 million to 50

Tone
Neutral 50/100
Event
Regulatory and legal
Published
23 Jun 2026 21:11
Source
Stock Titan
GlobeNewswire Direct company coverage

20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

20/20 BioLabs, Inc. (Nasdaq: AIDX) has launched a new monthly investor webinar series to enhance transparency and communication with shareholders. The series will commence on July 1, 2026, and will be held on the first Wednesday of each month to provide updates on the company's p

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 21:09
Source
GlobeNewswire
Stock Titan Direct company coverage

20/20 Biolabs (NASDAQ: AIDX) asks shareholders to raise authorized shares to 500M

20/20 Biolabs (AIDX) is seeking shareholder approval to increase its authorized common stock from 50 million to 500 million shares at its 2026 Annual Meeting. This action aims to replenish the share pool for future issuance, including potential conversions of Series E preferred s

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jun 2026 20:10
Source
Stock Titan
Minichart Direct company coverage

20/20 Biolabs, Inc. Files Form 8-K Announcing Amended and Restated Bylaws and Nasdaq Listing as Emerging Growth Company

20/20 Biolabs, Inc. (Nasdaq: AIDX) has filed a Form 8-K announcing an amendment to its bylaws, reducing the quorum required for a shareholder meeting from a majority to one-third of outstanding shares. This change, approved on May 19, 2026, has significant implications for corpor

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 14:38
Source
Minichart
The Chronicle-Journal Direct company coverage

20/20 Biolabs, Inc. - Common Stock (Nasdaq:AIDX) Stock Quote

This article provides a real-time stock quote for 20/20 Biolabs, Inc. (Nasdaq: AIDX), showing its current trading price, daily range, and recent performance metrics. It also includes a list of top news and press releases related to the company, covering financial results, new pro

Tone
Neutral 50/100
Event
Earnings
Published
27 May 2026 12:38
Source
The Chronicle-Journal
Stock Titan Direct company coverage

20/20 Biolabs (NASDAQ: AIDX) cuts quorum for shareholder meetings

20/20 Biolabs, Inc. (NASDAQ: AIDX) has amended its bylaws to reduce the shareholder quorum requirement for stockholder meetings from a majority of shares outstanding to one-third. This change aims to facilitate the company's ability to conduct official business at meetings, espec

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 09:19
Source
Stock Titan
MEXC Exchange Direct company coverage

AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for 20/20 Biolabs, Inc. (AIDX) on the NASDAQ, showing it trading at $1.01 with a 14.52% decrease. It details key market data, including market cap, volume, and recent price changes, along with a company overview and instructio

Tone
Negative 30/100
Event
Market update
Published
24 May 2026 07:10
Source
MEXC Exchange
Sahm Direct company coverage

20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

20/20 Biolabs, Inc. announced emergency planning to establish Ebola and Hantavirus testing in its CAP-accredited CLIA laboratory, should public health agencies require assistance. The company plans to leverage its experience from the COVID-19 pandemic, during which it processed o

Tone
Positive 67/100
Event
Balance sheet
Published
24 May 2026 05:39
Source
Sahm
Finviz Direct company coverage

AIDX - 20/20 Biolabs Inc Stock Price and Quote

This page provides a detailed overview of 20/20 Biolabs Inc. (AIDX) stock, including its latest price, performance metrics, and key financial data. It also lists recent news and corporate filings, highlighting the company's activities in medical devices and its initiatives in tes

Tone
Positive 60/100
Event
Market update
Published
23 May 2026 17:09
Source
Finviz
Timothy Sykes Direct company coverage

AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling

20/20 Biolabs Inc. (AIDX) experienced a significant stock slide of -15.35% due to negative trial data and strong selling pressure. Analyst sentiment is negative, citing weak fundamentals, razor-thin gross profit, and a high-risk early-stage healthcare AI diagnostics position. The

Tone
Negative 29/100
Event
Earnings
Published
23 May 2026 15:08
Source
Timothy Sykes
Investing.com Direct company coverage

20/20 Biolabs stock surges on Ebola testing plans

20/20 Biolabs Inc. (NASDAQ:AIDX) shares surged 16% in premarket trading after the company announced plans to develop Ebola and Hantavirus testing capabilities. The company is evaluating PCR test kits and existing equipment to meet potential demands, leveraging its experience from

Tone
Positive 71/100
Event
Market update
Published
23 May 2026 04:08
Source
Investing.com
Stock Titan Direct company coverage

20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results

20/20 Biolabs (AIDX) filed a prospectus supplement to register 10.105 million shares for resale by certain stockholders and included its Form 10-Q for Q1 2026. The company reported a net loss of $2,174,836 for the quarter and identified material weaknesses in internal controls, w

Tone
Negative 38/100
Event
Earnings
Published
22 May 2026 21:40
Source
Stock Titan